News
SPPI
1.030
0.00%
0.000
Spectrum Pharmaceuticals Inc: Statement of changes in beneficial ownership of securities
Press release · 08/01/2023 22:03
*News On Spectrum Pharmaceuticals Inc. (SPPI) Now Under ASRT
Dow Jones · 08/01/2023 21:08
Spectrum Pharmaceuticals Inc: Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities
Press release · 08/01/2023 13:02
Spectrum Pharmaceuticals Inc: Current report
Press release · 08/01/2023 11:06
Spectrum Pharmaceuticals Inc: Current report
Press release · 07/28/2023 00:01
Buy Spectrum Pharmaceuticals For Exposure To Assertio Holdings
Seeking Alpha · 07/24/2023 08:56
Spectrum Pharmaceuticals Inc: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Press release · 07/20/2023 13:02
*Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote "FOR" Proposed Transaction With Assertio Holdings, Inc.
Dow Jones · 07/20/2023 11:00
Press Release: Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Spectrum Pharmaceuticals Stockholders Vote "FOR" Proposed Transaction with Assertio Holdings, Inc.
Dow Jones · 07/20/2023 11:00
Press Release: Independent Proxy Advisory Firms -2-
Dow Jones · 07/20/2023 11:00
Assertio's Small Asset Acquisition Strategy Is Risky, But It May Pay Off
Seeking Alpha · 07/19/2023 07:24
Spectrum Pharmaceuticals Inc: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Press release · 07/12/2023 20:01
Spectrum Pharmaceuticals Inc: Report of proposed sale of securities
Press release · 06/23/2023 21:16
More
Webull provides a variety of real-time SPPI stock news. You can receive the latest news about Spectrum Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About SPPI
Spectrum Pharmaceuticals, Inc. is a commercial stage biopharmaceutical company. The Company is focused on acquiring, developing, and commercializing targeted oncology therapies. The Company's product portfolio consists of one commercial product and product candidates for the treatment of cancer patients. Its commercial product candidate includes ROLVEDON (eflapegrastim), which is a long-acting granulocyte colony-stimulating factor (G-CSF) that employs a proprietary LAPSCOVERY technology designed to enhance the duration of therapeutic effects and reduce the frequency of administration. ROLVEDON is FDA-approved for the treatment of adult patients with chemotherapy-induced neutropenia. Its development pipeline includes Poziotinib is a novel, pan-HER inhibitor that is designed to irreversibly block signaling through the Epidermal Growth Factor Receptor (EGFR) family of TKIs, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations.